Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHYF) EBITDA (2019 - 2025)

Historic EBITDA for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to -$28.8 million.

  • Innate Pharma's EBITDA fell 157.46% to -$28.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$118.1 million, marking a year-over-year decrease of 2297.27%. This contributed to the annual value of -$55.1 million for FY2024, which is 30431.71% down from last year.
  • Latest data reveals that Innate Pharma reported EBITDA of -$28.8 million as of Q2 2025, which was down 157.46% from -$52.9 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's EBITDA peaked at $7.5 million during Q2 2021, and registered a low of -$59.1 million during Q4 2022.
  • Its 5-year average for EBITDA is -$27.8 million, with a median of -$28.6 million in 2024.
  • As far as peak fluctuations go, Innate Pharma's EBITDA soared by 18184.34% in 2021, and later tumbled by 643822.73% in 2024.
  • Innate Pharma's EBITDA (Quarter) stood at -$52.0 million in 2021, then dropped by 13.69% to -$59.1 million in 2022, then soared by 86.23% to -$8.1 million in 2023, then crashed by 549.05% to -$52.9 million in 2024, then skyrocketed by 45.55% to -$28.8 million in 2025.
  • Its EBITDA stands at -$28.8 million for Q2 2025, versus -$52.9 million for Q4 2024 and -$28.3 million for Q2 2024.